{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T04:05:31Z","timestamp":1746504331485,"version":"3.40.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"am","delay-in-days":411,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UM1TR004406"],"award-info":[{"award-number":["UM1TR004406"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000223","name":"Muscular Dystrophy Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000223","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lipidjournal.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jacl.2024.12.003","type":"journal-article","created":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T04:09:10Z","timestamp":1734235750000},"page":"310-319","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring the impact of insurance switching on the cost-effectiveness of population genetic screening for familial hypercholesterolemia to US payers"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8394-3917","authenticated-orcid":false,"given":"Lauren E.","family":"Hendy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa P.","family":"Spees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Casey","family":"Tak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delesha M.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen C.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan C.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.jacl.2024.12.003_bib0001","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013225","article-title":"Diagnosis and treatment of heterozygous familial hypercholesterolemia","volume":"8","author":"McGowan","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"16","key":"10.1016\/j.jacl.2024.12.003_bib0002","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa1816454","article-title":"20-year follow-up of statins in children with familial hypercholesterolemia","volume":"381","author":"Luirink","year":"2019","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.jacl.2024.12.003_bib0003","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMe1611081","article-title":"What should be the screening strategy for familial hypercholesterolemia?","volume":"375","author":"McCrindle","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2024.12.003_bib0004","unstructured":"\u201cTier 1 genomics applications and their importance to public health | CDC.\u201d Accessed: Mar. 02, 2022. [Online]. Available: https:\/\/www.cdc.gov\/genomics\/implementation\/toolkit\/tier1.htm."},{"issue":"4","key":"10.1016\/j.jacl.2024.12.003_bib0005","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1001\/jama.2017.8543","article-title":"Cascade screening for familial hypercholesterolemia and the use of genetic testing","volume":"318","author":"Knowles","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2024.12.003_bib0006","article-title":"Patient experiences align with the familial hypercholesterolemia global call to action","volume":"10","author":"Jones","year":"2022","journal-title":"Am J Prev Cardiol"},{"issue":"21","key":"10.1016\/j.jacl.2024.12.003_bib0007","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1161\/CIRCULATIONAHA.117.032321","article-title":"Prevalence and predictors of cholesterol screening, awareness, and statin treatment among us adults with familial hypercholesterolemia or other forms of severe dyslipidemia (1999-2014)","volume":"137","author":"Bucholz","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2024.12.003_bib0008","unstructured":"N. Rao, W.D. Dotson, and M.J. Khoury, \u201cPopulation-based genomic screening programs: the need for optimal implementation to ensure health equity | Blogs | CDC.\u201d 2023. Accessed: Feb. 02, 2024. [Online]. Available: https:\/\/blogs.cdc.gov\/genomics\/2023\/06\/20\/population-based-genomic\/."},{"issue":"8","key":"10.1016\/j.jacl.2024.12.003_bib0009","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/s41591-020-0982-5","article-title":"Population genetic screening efficiently identifies carriers of autosomal dominant diseases","volume":"26","author":"Grzymski","year":"2020","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.jacl.2024.12.003_bib0010","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.3390\/jpm12081228","article-title":"Lessons learned from the pilot phase of a population-wide genomic screening program: building the base to reach a diverse cohort of 100,000 participants","volume":"12","author":"Allen","year":"2022","journal-title":"J Pers Med"},{"issue":"5","key":"10.1016\/j.jacl.2024.12.003_bib0011","doi-asserted-by":"crossref","first-page":"585","DOI":"10.7326\/M22-0846","article-title":"Population genomic screening for three common hereditary conditions\u202f: a cost-effectiveness analysis","volume":"176","author":"Guzauskas","year":"2023","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacl.2024.12.003_bib0012","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1038\/s41598-024-53121-0","article-title":"The value-based price of transformative gene therapy for sickle cell disease: a modeling analysis","volume":"14","author":"Morgan","year":"2024","journal-title":"Sci Rep"},{"issue":"Suppl 2","key":"10.1016\/j.jacl.2024.12.003_bib0013","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/hae.14425","article-title":"Alternative payment models for durable and potentially curative therapies: the case of gene therapy for haemophilia A","volume":"28","author":"Goodman","year":"2022","journal-title":"Haemophilia"},{"issue":"8","key":"10.1016\/j.jacl.2024.12.003_bib0014","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1001\/jamacardio.2021.1301","article-title":"Limited-variant screening vs comprehensive genetic testing for familial hypercholesterolemia diagnosis","volume":"6","author":"Sturm","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacl.2024.12.003_bib0015","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2147\/CEOR.S76972","article-title":"Medical costs associated with cardiovascular events among high-risk patients with hyperlipidemia","volume":"7","author":"Bonafede","year":"2015","journal-title":"Clinicoecon Outcomes Res"},{"issue":"6","key":"10.1016\/j.jacl.2024.12.003_bib0016","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care: the Framingham Heart Study","volume":"117","author":"D'Agostino","year":"2008","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.jacl.2024.12.003_bib0017","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1161\/CIRCULATIONAHA.108.816694","article-title":"Predicting the 30-year risk of cardiovascular disease: the framingham heart study","volume":"119","author":"Pencina","year":"2009","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.jacl.2024.12.003_bib0018","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.3390\/jcm8071080","article-title":"Incidence of cardiovascular disease in patients with familial hypercholesterolemia phenotype: analysis of 5 years follow-up of real-world data from >1.5 million patients","volume":"8","author":"Masana","year":"2019","journal-title":"J Clin Med"},{"issue":"19","key":"10.1016\/j.jacl.2024.12.003_bib0019","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.2015.15629","article-title":"Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US preventive services task force","volume":"316","author":"Chou","year":"2016","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.jacl.2024.12.003_bib0020","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jacc.2016.04.054","article-title":"Statins in familial hypercholesterolemia: consequences for coronary artery disease and all-cause mortality","volume":"68","author":"Besseling","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacl.2024.12.003_bib0021","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.010376","article-title":"Adherence to statin therapy among us adults between 2007 and 2014","volume":"8","author":"Colantonio","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.jacl.2024.12.003_bib0022","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/MLR.0000000000001020","article-title":"Risk factors for early disenrollment from colorado's affordable care act marketplace","volume":"57","author":"Gordon","year":"2019","journal-title":"Med Care"},{"issue":"2017-11","key":"10.1016\/j.jacl.2024.12.003_bib0023","article-title":"Measuring the true impact of job loss on future earnings","author":"Krolikowski","year":"2017","journal-title":"Econ Commentary"},{"issue":"2","key":"10.1016\/j.jacl.2024.12.003_bib0024","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.0320","article-title":"Trends in disenrollment and reenrollment within us commercial health insurance plans, 2006-2018","volume":"5","author":"Fang","year":"2022","journal-title":"JAMA Network Open"},{"issue":"5","key":"10.1016\/j.jacl.2024.12.003_bib0025","first-page":"612","article-title":"Health plan enrollment and disenrollment of individuals with and without established chronic disease in a u.s. commercially insured and medicare advantage population","volume":"25","author":"Chung","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.jacl.2024.12.003_bib0026","unstructured":"Cha, Amy E. and Cohen, Robin A., \u201cDemographic variation in health insurance coverage: United States, 2020,\u201d National Health Statistics Reports 169, Feb. 2022. Accessed: Mar. 13, 2023. [Online]. Available: https:\/\/www.cdc.gov\/nchs\/data\/nhsr\/nhsr169.pdf."},{"key":"10.1016\/j.jacl.2024.12.003_bib0027","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12872-016-0190-x","article-title":"Clinical and economic burden associated with cardiovascular events among patients with hyperlipidemia: a retrospective cohort study","volume":"16","author":"Fox","year":"2016","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.jacl.2024.12.003_bib0028","unstructured":"\u201cHow BLS measures price change for medical care services in the consumer price index : U.S. bureau of labor statistics.\u201d 2023. Accessed: Feb. 02, 2024. [Online]. Available: https:\/\/www.bls.gov\/cpi\/factsheets\/medical-care.htm."},{"issue":"9","key":"10.1016\/j.jacl.2024.12.003_bib0029","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/jama.2020.0734","article-title":"US health care spending by payer and health condition, 1996-2016","volume":"323","author":"Dieleman","year":"2020","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.jacl.2024.12.003_bib0030","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD012502.pub2","article-title":"Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events","author":"Zhan","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1016\/j.jacl.2024.12.003_bib0031","first-page":"750","article-title":"Insurance switching and mismatch between the costs and benefits of new technologies","volume":"23","author":"Cutler","year":"2017","journal-title":"Am J Manag Care"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287424002903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287424002903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T16:45:33Z","timestamp":1746463533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287424002903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1933287424002903"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2024.12.003","relation":{},"ISSN":["1933-2874"],"issn-type":[{"type":"print","value":"1933-2874"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring the impact of insurance switching on the cost-effectiveness of population genetic screening for familial hypercholesterolemia to US payers","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2024.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}